Little for Pharma in India's budgetary fiscal measures, says OPPI
Despite hopes that the Indian government would do something for the country’s pharmaceutical industry as part of its 2013/14 budgetary proposals, there was nothing of significance for the health care sector, according to the trade group the Organization of Pharmaceutical Producers of India (OPPI).
In its Pre-Budget Memorandum, the OPPI proposed budgetary/fiscal measures and support in the following five key areas: infrastructure building; improving access to medicines; reduction in transaction costs; incentivizing R&D; and reduction in tax burden and other measures
However, the OPPI said it appreciated the following announcements of the Finance Minister in his budget speech:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze